Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$27,000.00

Investigating the relationship between tranexamic acid and cancer outcomes in patients who have undergone surgery for intraabdominal cancer

EF 2024-25

Résumé
Perioperative bleeding and blood transfusions are common in cancer surgery, with evidence suggesting that red blood cell (RBC) transfusions may negatively impact cancer outcomes by promoting tumor growth, attachment, and spread. This is attributed to transfusion-related immunomodulation (TRIM), which involves both proinflammatory and immunosuppressive effects. Tranexamic acid (TXA), a synthetic antifibrinolytic agent, reduces bleeding by inhibiting plasmin, offering a potential strategy to minimize transfusion-related risks in cancer patients. While TXA is widely used and does not increase venous thromboembolism (VTE) risk in cancer patients, its effect on long-term outcomes like overall survival (OS) and disease-free survival (DFS) remains unexplored. Conversely, low molecular weight heparin (LMWH) has demonstrated antithrombotic and antimetastatic benefits, raising concerns that TXA mechanism may adversely impact cancer survival. However, there is some contradictory evidence suggesting TXA reduces cancer cell viability. The objective of this study is to explore the relationship of TXA and cancer outcomes, addressing a critical gap in the literature, providing evidence to guide TXA use in cancer surgery and optimize personalized perioperative care. We will first conduct a systematic review of pre-clinical and clinical studies on the effect of TXA on tumor biology in pre-clinical and clinical studies. We will then evaluate the independent effect of TXA on OS and DFS in patients who underwent major abdominal surgery for cancer and were randomized to receive TXA or not.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530271
Name
Ivankovic Victoria
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the relationship between tranexamic acid and cancer outcomes in patients who have undergone surgery for intraabdominal cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Surgery; Survival; Tranexamic Acid; Tumor Biology
Abstract
Perioperative bleeding and blood transfusions are common in cancer surgery, with evidence suggesting that red blood cell (RBC) transfusions may negatively impact cancer outcomes by promoting tumor growth, attachment, and spread. This is attributed to transfusion-related immunomodulation (TRIM), which involves both proinflammatory and immunosuppressive effects. Tranexamic acid (TXA), a synthetic antifibrinolytic agent, reduces bleeding by inhibiting plasmin, offering a potential strategy to minimize transfusion-related risks in cancer patients. While TXA is widely used and does not increase venous thromboembolism (VTE) risk in cancer patients, its effect on long-term outcomes like overall survival (OS) and disease-free survival (DFS) remains unexplored. Conversely, low molecular weight heparin (LMWH) has demonstrated antithrombotic and antimetastatic benefits, raising concerns that TXA mechanism may adversely impact cancer survival. However, there is some contradictory evidence suggesting TXA reduces cancer cell viability. The objective of this study is to explore the relationship of TXA and cancer outcomes, addressing a critical gap in the literature, providing evidence to guide TXA use in cancer surgery and optimize personalized perioperative care. We will first conduct a systematic review of pre-clinical and clinical studies on the effect of TXA on tumor biology in pre-clinical and clinical studies. We will then evaluate the independent effect of TXA on OS and DFS in patients who underwent major abdominal surgery for cancer and were randomized to receive TXA or not.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ivankovic, Victoria
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~